Implementation of personalized medicine in a context of moral hazard and uncertainty about treatment efficacy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Annemans, L., Redekop, K., & Payne, K. (2013). Current methodological issues in the economic assessment of personalized medicine. Value Health, 16(6), 20–26.
Antoñanzas, F., Juárez-Castellá, C. A., & Rodríguez-Ibeas, R. (2015). Some economics on personalized and predictive medicine. European Journal of Health Economics, 16(9), 985–994.
Antoñanzas, F., Juárez-Castellá, C. A., & Rodríguez-Ibeas, R. (2016). Implementing personalized medicine with asymmetric information on prevalence rates. Health Economics Review, 6, 35.
Antoñanzas, F., Rodrí-guez-Ibeas, R., & Juárez-Castellá, C. A. (2018). Personalized medicine and pay for performance: Should pharmaceutical firms be fully penalized when treatment fails? PharmacoEconomics, 36(7), 733–743.
Antoñanzas, F., Juárez-Castellá, C. A., & Rodrí-guez-Ibeas, R. (2019). Pre-approval incentives to promote adoption of personalized medicine: A theoretical approach. Health Economics Review, 9, 28.
Barros, P. P. (2011). The simple economics of risk sharing agreements between the NHS and the pharmaceutical industry. Health Economics, 20, 461–470.
Belleflamme, P., & Peitz, M. (2015). Industrial organization: markets and strategies. Cambridge: Cambridge University Press.
Bertucci, F., Houlgatte, R., Benziane, A., Granjeaud, S., Adélaïde, J., Tagett, R., et al. (2000). Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Human Molecular Genetics, 9(20), 2981–2991.
Bertucci, F., Finetti, P., Cervera, N., Maraninchi, D., Viens, P., & Birnbaum, D. (2006). Gene expression profiling and clinical outcome in breast cancer. Omics, 10(4), 429–443.
Cournot, A. A. (1838). Recherches sur les principes mathématiques de la théorie des richesses (Researches into the Mathematical Principles of the Theory of Wealth). NT Bacon: Initially published. in French.
Danzon, P., & Towse, A. (2002). The economics of gene therapy and pharmacogenetics. Value in Health, 5(1), 5–13.
Danzon, P., & Towse, A. (2003). Differential pricing for pharmaceuticals: Reconciling access. R&D and patents, International Journal of Healthcare Finance and Economics, 3, 183–205.
Danzon, P., Towse, A., & Mestre-Ferrandiz, J. (2015). Value-based differential pricing: Efficient prices for drugs in a global context. Health Economics, 24, 294–301.
Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A.-P., Hornberger, J., et al. (2012). Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: A report of the ISPOR Personalized Medicine Special Interest Group. Value in Health, 15(8), 1162–1171.
Garrison, L. P., & Austin, M. F. (2007). The economics of personalized medicine: A model of incentives for value creation and capture. Drug Information Journal: DIJ/Drug Information Association, 41(4), 501–509.
Garrison, L. P., & Towse, A. (2014). Economics of personalized medicine: Pricing and reimbursement policies as a potential barrier to development and adoption, Economics of. In Anthony J. Culyer (Ed.), Encyclopedia of Health Economics (Vol. 2, pp. 484–490). Amsterdam: Elsevier.
Garrison, L. P., & Towse, A. (2017). Value-based pricing and reimbursement in personalized healthcare: Introduction to the basic health economics. Journal of Personalized Medicine, 7(3), 1–10.
Goetz, L. H., & Schork, N. J. (2018). Personalized medicine: motivation, challenges, and progress. Fertility and Sterility, 109(6), 952–963.
Hatz, M. H. M., Schremser, K., & Rogowski, W. K. (2014). Is individualized medicine more cost-effective? A systematic review, PharmacoEconomics, 32(5), 443–455.
Hendricks-Sturrup, R. M., & Lu, C. Y. (2019). Understanding implementation challenges to genetic testing for familial hypercholesterolemia in the United States. Journal of Personalized Medicine, 9(1), 9.
Hornberger, J., Cosler, L. E., & Lyman, G. H. (2005). Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymphnode-negative, estrogen-receptor-positive, early-stage breast cancer. American Journal of Managed Care, 11, 313–324.
Kirchheiner, J., Bauer, S., Meineke, I., et al. (2002). Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics, 12(2), 101–109.
Jørgensen, J. T. (2019). Regulatory Requirements for Companion Diagnostics and Drug-Diagnostic Codevelopment in the United States. In Companion and Complementary Diagnostics (pp. 307–318). Academic Press.
Knowles, L., Luth, W., & Bubela, T. (2017). Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges. Journal of Law and the Biosciences, 4(3), 453–506.
Lam, Y.W. (2013). Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice, ISRN pharmacology, Article ID 641089, 17 pages.
Lièvre, A., Bachet, J. B., Le Corre, D., et al. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Research, 66(8), 3992–3995.
Miller, I., Ashton-Chess, J., Spolders, H., Fert, V., Ferrara, J., et al. (2011). Market access challenges in the EU for high medical value diagnostic tests. Personalized Medicine, 8(2), 137–148.
O’Donnell, J. C. (2013). Personalized medicine and the role of health economics and outcomes research: Issues, applications, emerging trends, and future research. Value in Health, 16(6), S1–S3.
Postma, M. J., Boersma, C., Vandijck, D., Vegter, S., Le, H. H., & Annemans, L. (2011). Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 11(4), 367–369.
Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product. Draft Guidance for Industry and Food and Drug Administration Staff. Document issued on: July 15, 2016.
Scott Morton, F., & Seabright, P. (2013). Research into biomarkers: how does drug procurement affect the design of clinical trials? Health Management, Policy and Innovation, 1(3), 1–15.
Tardif, J. C., Rhainds, D., Brodeur, M., Feroz Zada, Y., Fouodjio, R., Provost, S., et al. (2016). Genotype-dependent effects of dalcetrapib on cholesterol efflux and inflammation: Concordance with clinical outcomes. Circulation: Cardiovascular Genetics, 9(4), 340–348.
Towse, A., & Garrison, L. P. (2013). Economic incentives for evidence generation: promoting an efficient path to personalized medicine. Value in Health, 6(6), S39–S43.